E-MAIL UPDATES

Click here to join

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 06 Apr 2022 - From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's Executive Director and CEO, Marc Voigt.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 30 Mar 2022 - Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for Immutep's lead drug, eftilagimod alpha.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 30 Mar 2022 - Executive Director and CEO Marc Voigt discusses encouraging results in second-line non-small cell lung cancer.

Immutep Limited (ASX: IMM, NASDAQ: IMMP), 28 Mar 2022 - Executive Director and CEO, Marc Voigt speaks to Naureen Quibria, PhD. of Maxim Group about LAG-3 and an overview of the company outlining future plans

Frédéric Triebel, MD, PhD, Immutep Paris, France, discusses the TACTI-002 and TACTI-003 trials - Eftilagimod alpha for metastatic head and neck squamous cell carcinoma

Frédéric Triebel, MD, PhD, Immutep Paris, France, discusses the final results from the Phase IIb AIPAC trial of eftilagimod alpha vs placebo with chemo for HR+ HER2- MBC

Marc Voigt, Chief Executive Officer of Immutep (ASX:IMM; NASDAQ: IMMP) presents at the Bell Potter Healthcare Conference 2021

Immutep with Proactive at the ASX Small and Mid Cap Conference, Immutep Ltd's Marc Voigt speaks with Proactive at the ASX Small and Mid Cap Conference - September 2021.

Listen to the Spotify Podcast Interview of Dr. Frederic Triebel by Neil Canavan “Immutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) Stage “

Immutep Limited (ASX: IMM; NASDAQ: IMMP), 18 Aug 2021 - Bell Direct’s Jessica Amir speaks to Immutep's Executive Director and CEO, Marc Voigt

Immutep Limited (ASX: IMM; NASDAQ: IMMP) 04 May 2021 - CEO and Executive Director Marc Voigt speaks with Share Cafe's Tim McGowen about Immutep’s leading position within the LAG-3 competitive landscape

Finance News Network Interview, 29 Mar 2021, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial

Benzinga Biotech Small Cap Conference with CEO Marc Voigt, Wednesday, 24 March 2021, Immutep Limited (ASX: IMM, NASDAQ:IMMP) - CEO Presentation

Ausbiz Interview with CEO Marc Voigt, 17 March 2021, Immutep Limited (ASX: IMM; NASDAQ:IMMP) - Immutep Collaborates with US-based Merck & Co

Finance News Network Interview, 27 Jan 2021, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt analyses December's breast cancer data, and provides an update on efti's position and outlook

Immutep: fighting the good fight, 17 December 2020 - CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments

Finance News Network Interview, 03. Dec 2020, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt provides an update on the company, discussing a recent capital raise and results in lung cancer and head and neck cancer.

ASX Small and Mid-Cap Virtual Conference – Presentation

Interview with 180 Markets, 26 August 2020 - 180 Markets Speaks with Immutep CEO Marc Voigt about their LAG-3 Cancer treatment

Immutep CEO presentation BIO Asia-Taiwan, July 2020

Finance News Network Interview, 22. June 2020, Immutep (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.

CommSec Executive Series, 9 Mar 2020, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt

Bell Direct, 12 Mar. 2020, From the helm: Poised for a breakthrough - Immutep CEO Marc Voigt

Finance News Network Interview, 11. Mar. 2020, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.

Speaking at the recent JP Morgan Healthcare Conference 2020, Immutep Limited (ASX:IMM; NASDAQ:IMMP)

Finance News Network Interview, 5. Nov. 2019, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.

Finance News Network Interview, 2. Jul. 2019, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO & Executive Director, Marc Voigt, provides an update on the company's clinical trials, including its Phase IIb AIPAC study into metastatic breast cancer.

Finance News Network Interview, March 2019, Immutep (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt provides an update on its clinical trials, collaboration with large pharma and what they have planned for 2019

Finance News Network Interview, 12. Nov. 2018, Immutep Limited (ASX:IMM; NASDAQ:IMMP) Executive Director and CEO, Marc Voigt provides an update on the company's clinical trials, collaboration with large pharma and key milestones.

Your Money - Interview with Marc Voigt (Executive Director and CEO), 31. Oct. 2018

Finance News Network - Interview with Marc Voigt (Executive Director and CEO), 06. Sept. 2018

Brand movie - bringing new hope to patients

FNN – Interview with Immutep

Sky Business News - Interview with Marc Voigt (Executive Director and CEO), 30. April 18

Interview with Frédéric Triebel /CSO & CMO) & Marc Voigt (Executive Director and CEO)

CNBC - Interview with Marc Voigt (Executive Director and CEO)

Mode of Action of eftilagimod alpha (“IMP321”)

Sky Business News - Interview with Marc Voigt (Executive Director and CEO), 25. Nov. 15

The Business - Interview with Lucy Turnbull

Immutep with Proactive at the ASX Small and Mid Cap Conference

Immutep Limited (ASX: IMM; NASDAQ: IMMP), 04 May 2021 - CEO and Executive Director Marc Voigt speaks with Share Cafe's Tim McGowen about Immutep’s leading position within the LAG-3 competitive landscape

Finance News Network Interview, 29 Mar 2021, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial

Benzinga Biotech Small Cap Conference with CEO Marc Voigt, Wednesday, 24 March 2021, Immutep Limited (ASX: IMM, NASDAQ:IMMP) - CEO Presentation

Ausbiz Interview with CEO Marc Voigt, 17 March 2021, Immutep Limited (ASX: IMM; NASDAQ:IMMP) - Immutep Collaborates with US-based Merck & Co

Finance News Network Interview, 27 Jan 2021, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt analyses December's breast cancer data, and provides an update on efti's position and outlook

Immutep: fighting the good fight, 17 December 2020 - CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments

Finance News Network Interview, 03. Dec 2020, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO and Executive Director Marc Voigt provides an update on the company, discussing a recent capital raise and results in lung cancer and head and neck cancer.

ASX Small and Mid-Cap Virtual Conference – Presentation

Interview with 180 Markets, 26 August 2020 - 180 Markets Speaks with Immutep CEO Marc Voigt about their LAG-3 Cancer treatment

Immutep CEO presentation BIO Asia-Taiwan, July 2020

Finance News Network Interview, 22. June 2020, Immutep (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt provides an update on its clinical trials including metastatic breast cancer (MBC), its global leadership under Chief Scientist and Medical Officer, Professor Frederic Triebel, and the growing interest by big pharma in immuno-therapies.

CommSec Executive Series, 9 Mar 2020, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt

Bell Direct, 12 Mar. 2020, From the helm: Poised for a breakthrough - Immutep CEO Marc Voigt

Finance News Network Interview, 11. Mar. 2020, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.

Speaking at the recent JP Morgan Healthcare Conference 2020, Immutep Limited (ASX:IMM; NASDAQ:IMMP)

Finance News Network Interview, 5. Nov. 2019, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.

Finance News Network Interview, 2. Jul. 2019, Immutep Limited (ASX:IMM; NASDAQ:IMMP) CEO & Executive Director, Marc Voigt, provides an update on the company's clinical trials, including its Phase IIb AIPAC study into metastatic breast cancer.

Finance News Network Interview, March 2019, Immutep (ASX:IMM; NASDAQ:IMMP) CEO, Marc Voigt provides an update on its clinical trials, collaboration with large pharma and what they have planned for 2019

Finance News Network Interview, 12. Nov. 2018, Immutep Limited (ASX:IMM; NASDAQ:IMMP) Executive Director and CEO, Marc Voigt provides an update on the company's clinical trials, collaboration with large pharma and key milestones.

Your Money - Interview with Marc Voigt (Executive Director and CEO), 31. Oct. 2018

Finance News Network - Interview with Marc Voigt (Executive Director and CEO), 06. Sept. 2018

Brand movie - bringing new hope to patients

FNN – Interview with Immutep

Sky Business News - Interview with Marc Voigt (Executive Director and CEO), 30. April 18

Interview with Frédéric Triebel /CSO & CMO) & Marc Voigt (Executive Director and CEO)

CNBC - Interview with Marc Voigt (Executive Director and CEO)

Mode of Action of eftilagimod alpha (“IMP321”)

Sky Business News - Interview with Marc Voigt (Executive Director and CEO), 25. Nov. 15

The Business - Interview with Lucy Turnbull

Webcasts

Give it a listen.

Friday, August 27th, 2021

Listen to the Spotify Podcast Interview of Dr. Frederic Triebel by Neil Canavan “Immutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) Stage “

Wednesday, June 26th, 2019

Listen to a replay of the Immutep “KOL Call on Novel IO Therapy (eftilagimod alpha)” that took place on Wednesday, June 26, 2019

Tuesday, April 2nd, 2019

Listen to the webcast:  Update on Eftilagimod Alpha (IMP321)

Tuesday, March 26, 2019

Listen to the webcast and view the presentation "Immutep IMP761 Preclinical Results in Autoimmune Disease"

March, 19th, 2019

Listen to the webcast  “Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference”

Click here for the Presentation at Oppenheimer's 29th Annual Healthcare Conference (related to webcast)

September 7th, 2018

Immutep Newsmakers Presentation

May 29th/ 30th May

Immutep (ASX:IMM) Presentation, Clinical Results of Ongoing Melanoma Study and Update on Eftilagimod Alpha Clinical Development Strategy, May 2018